U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
Daratumumab for Severe Refractory Proliferative Glomerulonephritis with Monoclonal Immune Deposits (PGNMID). - ATC Abstracts
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study - Roy Vitkon, Dan Netanely, Shai Levi, Tomer
Columba Trial | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Current use of monoclonal antibodies in the treatment of multiple myeloma - Varga - 2018 - British Journal of Haematology - Wiley Online Library
PDF) Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
Everything you need to know about Daratumumab and Multiple Myeloma - Curetalks
Darzalex: Package Insert - Drugs.com
HCP Website | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
Case 966-- Clinical Chemistry Case
Daratumumab Biosimilar, Research Grade | CD38 mAb - Ushelf
SEBIA HYDRASHIFT 2/4 daratumumab test kit | Medical Supply Company
Siba El Hussein, MD on Twitter: "Daratumumab, an anti-CD38 IgG Kappa antibody, can cause light chain restriction in hematogones, proposed mechanism shown in video below: #hemepath #pathtwitter #mmsm @KirillLyapichev @sanamloghavi @KMirza @Xiaoqiong_Wang @
Detection of daratumumab and nivolumab by serum immunofixation... | Download Scientific Diagram
Electrophoretic patterns post daratumumab - Joanna Sheldon, Rachel D Wheeler, Ray Powles, 2018
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
How to get clearer test results on monoclonal antibodies
Diagnostics | Free Full-Text | Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis | NEJM
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Schematic presentation of double IFE Hydrashift Assay. (A) The... | Download Scientific Diagram
Diagnostics | Free Full-Text | Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study
